Familial hypocalciuric hypercalcemia

1982 ◽  
pp. 217-232 ◽  
Author(s):  
Stephen J. Marx
2019 ◽  
Author(s):  
Guechot Helene Hoth ◽  
Florence Kohler ◽  
Linda Humbert ◽  
Maxime Kwapich ◽  
Odou Marie Francoise ◽  
...  

2017 ◽  
Vol 33 (1) ◽  
pp. 32-41 ◽  
Author(s):  
Caroline M Gorvin ◽  
Fadil M Hannan ◽  
Treena Cranston ◽  
Helena Valta ◽  
Outi Makitie ◽  
...  

2016 ◽  
Vol 8 (3) ◽  
pp. 341-346 ◽  
Author(s):  
Anna Papadopoulou ◽  
Evangelia Gole ◽  
Katerina Melachroinou ◽  
Christos Meristoudis ◽  
Tania Siahanidou ◽  
...  

2020 ◽  
Vol 105 (5) ◽  
pp. 1393-1400
Author(s):  
Poonam Dharmaraj ◽  
Caroline M Gorvin ◽  
Astha Soni ◽  
Nick D Nelhans ◽  
Mie K Olesen ◽  
...  

Abstract Context Familial hypocalciuric hypercalcemia type 1 (FHH1) is caused by loss-of-function mutations of the calcium-sensing receptor (CaSR) and is considered a benign condition associated with mild-to-moderate hypercalcemia. However, the children of parents with FHH1 can develop a variety of disorders of calcium homeostasis in infancy. Objective The objective of this work is to characterize the range of calcitropic phenotypes in the children of a mother with FHH1. Methods A 3-generation FHH kindred was assessed by clinical, biochemical, and mutational analysis following informed consent. Results The FHH kindred comprised a hypercalcemic man and his daughter who had hypercalcemia and hypocalciuria, and her 4 children, 2 of whom had asymptomatic hypercalcemia, 1 was normocalcemic, and 1 suffered from transient neonatal hypocalcemia and seizures. The hypocalcemic infant had a serum calcium of 1.57 mmol/L (6.28 mg/dL); normal, 2.0 to 2.8 mmol/L (8.0-11.2 mg/dL) and parathyroid hormone of 2.2 pmol/L; normal 1.0 to 9.3 pmol/L, and required treatment with intravenous calcium gluconate infusions. A novel heterozygous p.Ser448Pro CaSR variant was identified in the hypercalcemic individuals, but not the children with hypocalcemia or normocalcemia. Three-dimensional modeling predicted the p.Ser448Pro variant to disrupt a hydrogen bond interaction within the CaSR extracellular domain. The variant Pro448 CaSR, when expressed in HEK293 cells, significantly impaired CaSR-mediated intracellular calcium mobilization and mitogen-activated protein kinase responses following stimulation with extracellular calcium, thereby demonstrating it to represent a loss-of-function mutation. Conclusions Thus, children of a mother with FHH1 can develop hypercalcemia or transient neonatal hypocalcemia, depending on the underlying inherited CaSR mutation, and require investigations for serum calcium and CaSR mutations in early childhood.


Sign in / Sign up

Export Citation Format

Share Document